Antara NewsState / PublicCenterFactual 88Objective 8223 hr. agoThe Food and Drug Monitoring Agency (BPOM) in Indonesia announced support for an mRNA-based dengue vaccine being developed by researchers from the University of Indonesia and Tsinghua University. The vaccine, still in the preclinical trial phase, has shown promising results in generating higher antibody titers against all four dengue virus serotypes compared to existing commercial vaccines. BPOM emphasized its commitment to ensuring the vaccine's safety and efficacy under Indonesia's Health Law No. 17 of 2023. Funding for the project comes from the Indonesia Endowment Fund for Education (LPDP) and PT Etana, with a total of Rp14 trillion (US$757 million) allocated annually for research. The agency's involvement aims to improve understanding of the project's standards and methods to provide better support.
Bias read (Center): The article presents information about a scientific development and governmental support without overtly favoring any political ideology. It focuses on technical aspects of the vaccine, regulatory processes, and funding sources, maintaining a balanced tone. While the collaboration between Indonesian
Why these scores (Factual 88 · Objective 82): Factuality is strong with specific statistics and quotes from BPOM head, aligning with cross-source consensus. Objectivity is good but includes some aspirational phrasing like 'we will make history,' which adds slight promotional tone despite overall neutrality.
Antara NewsState / PublicCenterFactual 85Objective 807 hr. ago Dengue vaccine shows ability to address infectious diseases: BPOMIndonesia's Food and Drug Monitoring Agency (BPOM) announced the development of an mRNA-based dengue vaccine prototype, highlighting the country's capacity for innovation in tackling infectious diseases. The vaccine was developed through a collaboration between the University of Indonesia, Tsinghua University, and PT Etana, supported by multiple stakeholders. BPOM emphasized the importance of early regulatory involvement in the development process to ensure compliance with global standards and accelerate product development while maintaining safety and efficacy. The initiative is part of broader strategic cooperation between Indonesia and China in vaccines, genomics, and health biotechnology. BPOM expressed commitment to supporting the project to create the world's first mRNA-based dengue vaccine.
Bias read (Center): The article presents factual information about a scientific development and regulatory involvement without overtly favoring any political side. It focuses on collaboration, innovation, and regulatory processes rather than partisan issues.
Why these scores (Factual 85 · Objective 80): Factuality is high as the article accurately reports BPOM's statements about the dengue vaccine prototype, collaboration details, and regulatory changes. Objectivity is slightly lower due to some promotional language like 'important milestone' and emphasis on Indonesia's innovation, though it remain
ID
